Physical Therapists in Incline Village, NV Accepting Medicare
7 Physical Therapists found. Showing 1 - 7
 Marie Louise Palu, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 797 Southwood Blvd, # 3, Incline Village, NV 89451 Phone: 775-833-1900 Fax: 775-833-0889 |
 Incline Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 797 Southwood Blvd, Suite Number 3, Incline Village, NV 89451 Phone: 775-833-1900 Fax: 775-833-0889 |
Everything Kids Pediatric Therapy Associates Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 776 Joyce Ln, Incline Village, NV 89451 Phone: 970-471-2816 Fax: 877-524-4110 |
Elisabeth Helen Brown, BAPPSC, MED Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 776 Joyce Ln, Incline Village, NV 89451 Phone: 775-833-9788 Fax: 775-833-9799 |
Rachel Bowdle Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 333 Village Blvd Ste 201, Incline Village, NV 89451 Phone: 775-831-1964 |
Rebecca L Stavis, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 889 Alder Ave, Suite 105, Incline Village, NV 89451 Phone: 775-831-6600 Fax: 775-831-6697 |
North Tahoe Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 889 Alder Ave, Suite 105, Incline Village, NV 89451 Phone: 775-831-6600 |
News Archive
PSCK9 inhibitors may provide benefit to atherosclerosis patients with high lipoprotein(a) levels
Lipoprotein(a) is a variant of LDL (low-density lipoprotein) cholesterol, and large amounts of data have shown that higher lipoprotein(a) levels are associated with an increased risk of cardiovascular events.
UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV
Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.
Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting
Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.
Scientists discover simple way to use light for steering killer immune cells toward tumors
The science behind harnessing the immune system to fight cancer is complicated, but a University of Rochester Medical Center laboratory discovered a simple, practical way to use light and optics to steer killer immune cells toward tumors.
New method to predict risk of breast cancer
Mayo Clinic researchers have found that certain structural features within breast tissue can indicate a woman's individual cancer risk. The findings appear online today in the Journal of Clinical Oncology.
› Verified 8 days ago
Chiropractors
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Optometrists